Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA User Fee Bill Up For Final Senate Action After House Passage

This article was originally published in The Pink Sheet Daily

Executive Summary

Senate is last step before the bill goes to the president; Rep. Dingell laments that legislators were “closer than ever before” on a tracking agreement but did not quite make it.

You may also be interested in...



Budget Reductions Target FDA Field Operations

President Obama’s fiscal 2016 budget request includes cuts to “low priority” enforcement, surveillance and other activities in the FDA human drugs and biologics programs, but still increases drug and biologics program budgets overall.

Budget Reductions Target FDA Field Operations

President Obama’s fiscal 2016 budget request includes cuts to “low priority” enforcement, surveillance and other activities in the FDA human drugs and biologics programs, but still increases drug and biologics program budgets overall.

FDA Field Operations Would Endure Reductions Under Budget

President Obama’s FY 2016 blueprint includes cuts to ‘low-priority’ enforcement, surveillance and other activities in FDA human drugs and biologics programs, but still increases those operations overall.

Related Content

Topics

UsernamePublicRestriction

Register

PS074313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel